Barclays
CADL icon

Barclays’s Candel Therapeutics CADL Stock Holding History

Barclays’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$752K Buy
72,074
+32,634
+83% +$362K ﹤0.01% 3234
2026
Q2 		$406K Buy
39,440
+27,741
+237% +$210K ﹤0.01% 3335
2026
Q1 		$57.3K Sell
11,699
-57,645
-83% -$314K ﹤0.01% 4265
2025
Q4 		$392K Buy
69,344
+9,749
+16% +$52.4K ﹤0.01% 3983
2025
Q3 		$304K Sell
59,595
-8,841
-13% -$51.1K ﹤0.01% 4089
2025
Q2 		$346K Buy
68,436
+37,114
+118% +$191K ﹤0.01% 3969
2025
Q1 		$177K Sell
31,322
-2,995
-9% -$24.5K ﹤0.01% 4124
2024
Q4 		$298K Buy
34,317
+5,629
+20% +$33.3K ﹤0.01% 4125
2024
Q3 		$199K Buy
28,688
+21,971
+327% +$136K ﹤0.01% 4293
2024
Q2 		$41.6K Buy
+6,717
New +$50.4K ﹤0.01% 4277

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Tanager Wealth Management
Tanager Wealth Management Goring On Thames, United Kingdom $1.2B AUM 12% 1-Year Est. Return
ACPLP
ACT Capital Partners, L.P. Wayne, Pennsylvania $154M AUM
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Barclays's CADL Position: Q3 2026 in Review

Barclays increased its Candel Therapeutics (CADL) stake by 83% in Q3 2026, buying an estimated $362K and bringing the position to 72,074 shares worth $752K. The position accounts for ﹤0.01% of the portfolio, ranked #3234.

Barclays first reported a position in CADL in Q2 2024 and has held it in 10 quarters since. 55 funds tracked by Wall St. Rank hold CADL as of Q3 2026.

  • Barclays held 72,074 shares of Candel Therapeutics worth $752K as of Q3 2026.
  • Barclays bought 32,634 Candel Therapeutics shares in Q3 2026, an estimated $362K.
  • Candel Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #3234 holding.
  • Barclays first reported a position in Candel Therapeutics in Q2 2024 and has held it in 10 quarters since.
  • 55 funds tracked by Wall St. Rank held Candel Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.